Noxopharm Résultats passés
Passé contrôle des critères 0/6
Noxopharm's earnings have been declining at an average annual rate of -14.4%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 5.2% per year.
Informations clés
-14.4%
Taux de croissance des bénéfices
13.9%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.0% |
| Taux de croissance des recettes | 5.2% |
| Rendement des fonds propres | -184.4% |
| Marge nette | -312.9% |
| Dernière mise à jour des bénéfices | 31 Dec 2023 |
Mises à jour récentes des performances passées
Pas de mise à jour
Recent updates
Ventilation des recettes et des dépenses
Comment Noxopharm gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -12 | 5 | 0 |
| 30 Sep 23 | 5 | -14 | 5 | 0 |
| 30 Jun 23 | 6 | -15 | 6 | 0 |
| 31 Mar 23 | 6 | -15 | 6 | 0 |
| 31 Dec 22 | 7 | -15 | 7 | 0 |
| 30 Sep 22 | 6 | -17 | 7 | 0 |
| 30 Jun 22 | 5 | -19 | 7 | 0 |
| 31 Mar 22 | 6 | -15 | 7 | 0 |
| 31 Dec 21 | 6 | -11 | 6 | 0 |
| 30 Sep 21 | 6 | -10 | 7 | 0 |
| 30 Jun 21 | 6 | -9 | 7 | 0 |
| 31 Mar 21 | 6 | -5 | 7 | 0 |
| 31 Dec 20 | 6 | 0 | 7 | 0 |
| 30 Sep 20 | 7 | 0 | 8 | 0 |
| 30 Jun 20 | 8 | 0 | 8 | 0 |
| 31 Mar 20 | 6 | -7 | 9 | 2 |
| 31 Dec 19 | 4 | -15 | 10 | 4 |
| 30 Sep 19 | 4 | -13 | 10 | 5 |
| 30 Jun 19 | 4 | -11 | 9 | 7 |
| 31 Mar 19 | 4 | -11 | 9 | 6 |
| 31 Dec 18 | 3 | -10 | 8 | 5 |
| 30 Sep 18 | 2 | -14 | 7 | 4 |
| 30 Jun 18 | 1 | -18 | 6 | 4 |
| 31 Mar 18 | 1 | -16 | 5 | 3 |
| 31 Dec 17 | 1 | -14 | 4 | 3 |
| 30 Sep 17 | 1 | -8 | 3 | 2 |
| 30 Jun 17 | 0 | -3 | 2 | 1 |
| 31 Mar 17 | 0 | -3 | 2 | 1 |
Des revenus de qualité: NOXO.F is currently unprofitable.
Augmentation de la marge bénéficiaire: NOXO.F is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: NOXO.F is unprofitable, and losses have increased over the past 5 years at a rate of 14.4% per year.
Accélération de la croissance: Unable to compare NOXO.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: NOXO.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Rendement des fonds propres
ROE élevé: NOXO.F has a negative Return on Equity (-184.44%), as it is currently unprofitable.